Ruiu et al., 2021 - Google Patents
Identification of TENM4 as a novel cancer stem cell-associated molecule and potential target in triple negative breast cancerRuiu et al., 2021
View HTML- Document ID
- 6084943318323339650
- Author
- Ruiu R
- Barutello G
- Arigoni M
- Riccardo F
- Conti L
- Peppino G
- Annaratone L
- Marchiò C
- Mengozzi G
- Calogero R
- Cavallo F
- Quaglino E
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Patients with triple negative breast cancer (TNBC) experience shorter overall survival compared to non-TNBC patients because of the high incidence of recurrences and metastases. This is due to the capacity of aggressive cancer cell …
- 101710036347 TENM4 0 title abstract description 169
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/12—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for modelling or simulation in systems biology, e.g. probabilistic or dynamic models, gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Das et al. | Nuclear respiratory factor 1 acting as an oncoprotein drives estrogen-induced breast carcinogenesis | |
Kim et al. | STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model | |
Wang et al. | Cd44 promotes lung cancer cell metastasis through erk–zeb1 signaling | |
Kang et al. | Cancer-associated fibroblast subgroups showing differential promoting effect on hnscc progression | |
Lee et al. | Upregulation of CD109 promotes the epithelial-to-mesenchymal transition and stemness properties of lung adenocarcinomas via activation of the hippo-YAP signaling | |
Peltanova et al. | Sensitivity to cisplatin in head and neck cancer cells is significantly affected by patient-derived cancer-associated fibroblasts | |
Tong et al. | LncRNA HCP5-encoded protein regulates ferroptosis to promote the progression of triple-negative breast cancer | |
Takahashi et al. | AKT3 is a novel regulator of cancer-associated fibroblasts in head and neck squamous cell carcinoma | |
Akinjiyan et al. | DDR2 expression in cancer-associated fibroblasts promotes ovarian cancer tumor invasion and metastasis through periostin-ITGB1 | |
Ruiu et al. | Identification of TENM4 as a novel cancer stem cell-associated molecule and potential target in triple negative breast cancer | |
Kupczyk et al. | PARP1 as a marker of an aggressive clinical phenotype in cutaneous melanoma—a clinical and an in vitro study | |
Oh et al. | Genome-wide transcriptomic analysis of non-tumorigenic tissues reveals aging-related prognostic markers and drug targets in renal cell carcinoma | |
Huang et al. | Pan-cancer analysis reveals SH3TC2 as an oncogene for colorectal cancer and promotes tumorigenesis via the MAPK pathway | |
Yunusova et al. | Comparative analysis of tumor-associated microRNAs and tetraspanines from exosomes of plasma and ascitic fluids of ovarian cancer patients | |
Tachon et al. | MEOX2 transcription factor is involved in survival and adhesion of glioma stem-like cells | |
Fan et al. | Siglec-15 as a new perspective therapy target in human giant cell tumor of bone | |
Koni et al. | Interleukin-3-receptor-α in triple-negative breast cancer (TNBC): an additional novel biomarker of TNBC aggressiveness and a therapeutic target | |
Lebedev et al. | Targeting ARID1A-deficient cancers: an immune-metabolic perspective | |
Sadeghi et al. | Differential B-cell receptor signaling requirement for adhesion of mantle cell lymphoma cells to stromal cells | |
Izraely et al. | The vicious cycle of melanoma-microglia crosstalk: inter-melanoma variations in the brain-metastasis-promoting Il-6/Jak/Stat3 signaling pathway | |
Yoon et al. | Sp1-induced FNBP1 drives rigorous 3D cell motility in EMT-type gastric cancer cells | |
Iommelli et al. | A reversible shift of driver dependence from EGFR to Notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors | |
Vargas-Accarino et al. | Spontaneous cell detachment and reattachment in cancer cell lines: an in vitro model of metastasis and malignancy | |
Treese et al. | S100A4 is a strong negative prognostic marker and potential therapeutic target in adenocarcinoma of the stomach and esophagus | |
Moiseeva et al. | Analysis of multiple drug resistance mechanism in different types of soft tissue sarcomas: assessment of the expression of ABC-transporters, MVP, YB-1, and analysis of their correlation with chemosensitivity of cancer cells |